Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study
Hirotoshi Iihara, Mototsugu Shimokawa, Hiroko Bando, Yoshimi Niwa, Yutaka Mizuno, Yoshihiro Kawaguchi, Mika Kitahora, Akari Murakami, Masaaki Kawai, Kazushige Ishida, Makoto Takeuchi, Kazuhiro Ishihara, Tomokazu Iyoda, Takumi Nakada, Atsuko Ogiso, Yasuyuki Kojima, Fumiyoshi Kumagai, Aya Sawa, Rintaro Mori, Kosuke Higuchi, T. Furuta, Yoshiaki Kamei, Masami Tsuchiya, Azusa Terasaki, Senri Yamamoto, Mai Kitazawa, Mai Okazaki, Akio Suzuki, Manabu Futamura
Abstract
Patients receiving trastuzumab deruxtecan require triple therapy, including mandatory NK1RA administration.
Topics & Concepts
AprepitantMedicineAntiemeticTrastuzumabNauseaVomitingRegimenGranisetronClinical endpointBreast cancerInternal medicineRandomized controlled trialOncologyAnesthesiaCancerNausea and vomiting managementGastric Cancer Management and OutcomesChemotherapy-related skin toxicity